SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced the presentation of an abstract at the Digestive Disease Week (DDW) annual meeting of positive pharmacodynamic study results indicating that, after seven days of pre-breakfast dosing, ZEGERID® (omeprazole/sodium bicarbonate) Capsules 40 mg/1100 mg produced significantly greater and significantly faster control of gastric acidity in patients with gastroesophageal reflux disease (GERD) than two comparator drugs. The clinical study evaluated the effect of morning dosing of immediate-release ZEGERID Capsules, Protonix® (pantoprazole sodium) Delayed-Release Tablets 40 mg and Prevacid® (lansoprazole) Delayed-Release Capsules 30 mg on 24-hour gastric acid control. The clinical data were presented by Colin W. Howden, M.D., Division of Gastroenterology, Northwestern University Feinberg School of Medicine, in a poster session on May 18, 2008.
